Skip to content

Effects of Marijuana on the quality of life of Cancer patients

Effectiveness of Medicinal Cannabis on the quality of life of Oncological patients

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-9zvptxg
Enrollment
Unknown
Registered
2023-03-28
Start date
2023-01-05
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anxiety

Interventions

The study is characterized by being a longitudinal clinical study in which quantitative data will be evaluated, such as the effects of the intervention with medical cannabis on the dependent variables
and who are in a situation of mental and physical suffering. In this way, in the design of this research, the participant will be in control of himself. It is also important to inform that treatment w
D26.528

Sponsors

Universidade Federal de São Paulo
Lead Sponsor
Universidade Federal de São Paulo
Collaborator

Eligibility

Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: People over 18 years of age; patients who will start treatment with medical cannabis; who are newly linked to cannabis associations; who have been diagnosed with cancer; and who are undergoing cancer treatment.

Exclusion criteria

Exclusion criteria: Interdicted and/or curated patients; under 18 years of age; using antidepressants or anxiolytics, and people undergoing palliative treatment.

Design outcomes

Primary

MeasureTime frame
It is expected to find effects of improvement in the quality of life of cancer patients undergoing treatment with medical cannabis through the WHOQOL-bref quality of life assessment instrument, based on the verification of a variation of at least 5% in the pre, post-intervention and follow-up.

Secondary

MeasureTime frame
It is expected to find a reduction in anxiety and depression symptoms among cancer patients using medical cannabis through the application of the depression, anxiety and stress scale (DASS-21), based on the observation of a variation of at least 5% in the pre, post intervention and follow-up measurements.

Countries

Brazil

Contacts

Public ContactAdriana Tucci

Universidade Federal de São Paulo

atucci@unifesp.br+55 (13) 3512-2700

Outcome results

None listed

Source: REBEC (via WHO ICTRP)